Update in Janssen v. Celltrion: Parties Stipulate that Celltrion Will Not Sell Remicade Biosimilar Before October 3, 2016

Janssen v. Celltrion (infliximab)

In a stipulation filed yesterday in Janssen v. Celltrion, Celltrion has agreed not to sell its Remicade biosimilar in the U.S. for use by doctors or patients before October 3, 2016, and the parties have agreed to dismiss all claims and defenses related to Defendants’ alleged violation of the BPCIA’s 180-day notice of commercial marketing provision (42 U.S.C. § 262(l)(8)(A)) as moot.

Big Molecule Watch will continue to follow and report on developments in this case.

Download PDF

Comments are closed.